Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany.MoreShow less
Profile & Fundamentals
Hims & Hers Health: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Hims & Hers Health Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.
Company profile record
Hims Hers Health Inc
Common Stock · Health Care · Health Care Services
Company
- Company / asset
- Hims Hers Health Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Services
- HQ
- 🇺🇸 United States
- Head office
- 2269 Chestnut Street, San Francisco, CA, United States, 94123
Leadership & scale
- Chief executive
- Mr. Andrew Dudum
- CEO year born
- 1988
- Full-time employees
- 2.4K
- Fiscal year end
- December
- IPO date
- 2019-09-13
Fundamentals snapshot
- Market Cap
- USD 6.8B
- P/E
- --
- Revenue (Q2 26)
- USD 753.2M
- Profit (Q2 26)
- USD -86.3M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 2.3B
- Shares in public float
- 213.7M
- Insider ownership
- 4.95%
Reporting & identifiers
- Symbol
- HIMS.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US4330001060
- Asset ID
- equity_66030d24-c4db-5de4-b6cd-c0c5afaa1703
Ownership
Shares Outstanding
Latest: 231.7M | Max: 248.1M | Min: 39.1M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
92.23%
213.7M latest reported shares
Insider Ownership
4.95%
Latest reported insider stake
Short Float
0.27%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2019-01-01 | 39,089,600 |
| 2020-01-01 | 79,311,900 |
| 2021-01-01 | 201,363,300 |
| 2022-01-01 | 206,140,300 |
| 2023-01-01 | 209,739,700 |
| 2024-01-01 | 240,725,400 |
| 2025-01-01 | 248,096,400 |
| 2026-01-01 | 231,746,100 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 26,337,158 | 11.29% | 2026-03-31 |
| Vanguard Portfolio Management, LLC | 10,183,813 | 4.36% | 2026-03-31 |
| Vanguard Capital Management, LLC | 9,339,711 | 4% | 2026-03-31 |
| Morgan Stanley - Brokerage Accounts | 8,889,088 | 3.81% | 2026-03-31 |
| State Street Corp | 7,460,023 | 3.2% | 2026-03-31 |
| Defiance ETFs, LLC | 7,424,258 | 3.18% | 2026-03-31 |
| iShares Core S&P Mid-Cap ETF | 7,422,263 | 3.18% | 2026-08-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 6,729,593 | 2.88% | 2026-08-31 |
| iShares Russell 2000 ETF | 5,498,189 | 2.36% | 2026-08-31 |
| JPMorgan Chase & Co | 5,240,816 | 2.25% | 2026-03-31 |
| Geode Capital Management, LLC | 5,198,779 | 2.23% | 2026-03-31 |
| Vanguard Small Cap Index | 4,876,172 | 2.09% | 2026-08-31 |
| Bank of America Corp | 4,357,672 | 1.87% | 2026-03-31 |
| UBS Group AG | 4,151,638 | 1.78% | 2026-03-31 |
| Vanguard MStar Small Cap Growth Indx Inv | 2,798,944 | 1.2% | 2026-08-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Recent financial results tell two conflicting stories: powerful top-line expansion alongside sudden accounting losses. Fiscal 2025 revenue surged fifty-nine percent to $2.35 billion, generating $128 million in net income. However, results reversed in early 2026, culminating in a trailing twelve-month net loss of $142 million. This earnings dislocation occurred because regulatory restrictions forced the company to stop selling lucrative compounded weight-loss drugs and start reselling brand-name therapies. While second-quarter 2026 revenue rose thirty-eight percent to $753 million, distributing branded products squeezed profit margins, proving that headline sales growth no longer guarantees immediate bottom-line cash flow.
Recent financial results tell two conflicting stories: powerful top-line expansion alongside sudden accounting losses. Fiscal 2025 revenue surged fifty-nine percent to $2.35 billion, generating $128 million in net income. However, results reversed in early 2026, culminating in a trailing twelve-month net loss of $142 million. This earnings dislocation occurred because regulatory restrictions forced the company to stop selling lucrative compounded weight-loss drugs and start reselling brand-name therapies. While second-quarter 2026 revenue rose thirty-eight percent to $753 million, distributing branded products squeezed profit margins, proving that headline sales growth no longer guarantees immediate bottom-line cash flow.
Revenue, Net Income, and Free Cash Flow
Latest: USD 2.3B | Max: USD 2.3B | Min: USD -107.7M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 63x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profit margins have experienced an acute, structural reset. Gross profit margins declined from a peak near eighty percent in 2024 to sixty-four percent by mid-2026. This drop was directly caused by product mix changes: distributing third-party branded medicines leaves far less profit than selling in-house formulations. Consequently, operating margins fell into negative territory as digital advertising and overhead outpaced gross profits. Returning to historical eighty percent gross margins is mathematically improbable; sustainable recovery requires gross margins to level off near sixty-five percent while automated fulfillment lowers ongoing administrative expenses.
Profit margins have experienced an acute, structural reset. Gross profit margins declined from a peak near eighty percent in 2024 to sixty-four percent by mid-2026. This drop was directly caused by product mix changes: distributing third-party branded medicines leaves far less profit than selling in-house formulations. Consequently, operating margins fell into negative territory as digital advertising and overhead outpaced gross profits. Returning to historical eighty percent gross margins is mathematically improbable; sustainable recovery requires gross margins to level off near sixty-five percent while automated fulfillment lowers ongoing administrative expenses.
Profitability Margins
Latest: 73.8% | Max: 82.0% | Min: <-100.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
73.8%
Gross profit / revenue
Operating Margin
4.5%
Operating income / revenue
Net Margin
5.5%
Net income / revenue
FCF Margin
3.2%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2018-12-31 | 26,679,000 | -75,243,000 | -57,330,000 |
| 2019-12-31 | 82,558,000 | -72,064,000 | -76,654,000 |
| 2020-12-31 | 148,757,000 | -18,114,000 | -6,712,000 |
| 2021-12-31 | 271,878,000 | -107,659,000 | -39,419,000 |
| 2022-12-31 | 526,916,000 | -65,678,000 | -33,778,000 |
| 2023-12-31 | 872,000,000 | -23,546,000 | 46,991,000 |
| 2024-12-31 | 1,476,514,000 | 126,038,000 | 198,334,000 |
| 2025-12-31 | 2,347,637,000 | 128,365,000 | 73,961,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 62.76 | Trailing four quarters |
| 2024-12-31 | 46.18 | Trailing four quarters |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2018-12-31 | 29.25 | -284 | -282.03 | -214.89 |
| 2019-12-31 | 54.03 | -90.14 | -87.29 | -92.85 |
| 2020-12-31 | 73.58 | -10.18 | -12.18 | -4.51 |
| 2021-12-31 | 75.22 | -42.31 | -39.6 | -14.5 |
| 2022-12-31 | 77.57 | -13.04 | -12.46 | -6.41 |
| 2023-12-31 | 81.99 | -3.38 | -2.7 | 5.39 |
| 2024-12-31 | 79.45 | 4.19 | 8.54 | 13.43 |
| 2025-12-31 | 73.84 | 4.5 | 5.47 | 3.15 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.